REG.F REMEGEN CO. LTD YC 1

Healthcare Diversified REITs Frankfurt Exchange
21.27 EUR
Close of Nov 12, 2026
6.77 12.79
Market cap
EUR 4.44B
P/E
6.1x
P/B
3.72x
ROE
19.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is REG.F undervalued?

Graham number
Price21.27
Graham value21.10
Premium0.8%

REG.F trades 0.8% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

REMEGEN CO. LTD YC 1 fundamental analysis

No fundamental analysis for REMEGEN CO. LTD YC 1 yet.

REMEGEN CO. LTD YC 1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About REMEGEN CO. LTD YC 1

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, ur…

Full company profile